Share

Xiangyu Medical Co.,Ltd Stocks

CN¥ 58.58Last Updated 27.04.2026

Issuer Rating

4/7
Performance

Modest

Risk

Limited

Recommendation

Hold

Market Cap

CN¥ 1.31B

Buy
Review
Evaluation
Target price
Dynamics
Performance
Growth
Dividends
Risks
CN¥ 58.58
Key Takeaways

Risk factor

Good trading liquidity

Data is available to registered users only
Data is available to registered users only

Profitability factor

Greatly overvalued vs peers

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Xiangyu Medical Co.,Ltd engages in the research, development, production, marketing, and sale of rehabilitation, physiotherapy, and pain management equipment to multinational organizations and small individual companies. It supplies equipment for phototherapy, electrotherapy, magnetotherapy, heat therapy, hydrotherapy, cryotherapy, wax therapy, steam therapy, sports therapy, air compression therapy, traction therapy, massage therapy, PT physical therapy, OT occupational therapy, children rehabilitation, rehab exercising, etc., as well as hydrocollators. The company exports its products to Europe, Africa, Australia, the Middle East, Southeast Asia, and other countries. Xiangyu Medical Co.,Ltd was founded in 2002 and is based in Anyang, China.

Company Valuation

Greatly overvalued
1/7

Based on key historical and expected multiples, the stock is greatly overvalued relative to its peers. In particular, the stock is overpriced on P/E, 'expensive' on EV/EB

Data is available to registered users only
Sign up to access detailed valuation

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis
X-channel

Buy

Sell

0 more stocks